Atomoxetine in the treatment of attention deficit hyperactivity disorder.
Atomoxetine (Strattera, Eli Lilly & Co.) is a highly selective noradrenaline reuptake inhibitor and the first nonstimulant medication to be approved for the treatment of attention deficit hyperactivity disorder. Currently, nine published clinical trials have documented the safety and efficacy of atomoxetine in the treatment of children, adolescents and adults with attention deficit hyperactivity disorder and data presented throughout the past year at national scientific meetings has further addressed its utility. This article reviews the available information on atomoxetine, accompanied by a discussion of its clinical use.
Kratochvil
Christopher J
CJ
University of Nebraska Medical Center, Omaha, NE 68198 5581, USA. ckratoch@unmc.edu
Vaughan
Brigette S
BS
Daughton
Joan M
JM
Mayfield-Jorgensen
Michelle L
ML
Burke
William J
WJ
D018759:Adrenergic Uptake Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D001523:Mental Disorders / Q000150:complications / Q000188:drug therapy / Q000523:psychology; D011437:Propylamines / Q000737:chemistry / Q000627:therapeutic use*
D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride